What is Olumiant (baricitinib)
Buy Olumiant (baricitinib). Olumiant (baricitinib) is used for treating several conditions. It helps patients with:
- Moderate to severe rheumatoid arthritis when other treatments don’t work or are not tolerated. It can be used alone or with methotrexate.
- moderate to severe atopic dermatitis in adults who need systemic therapy.
On November 19, 2020, the FDA granted emergency use authorization for Olumiant (baricitinib). It’s used with Veklury (remdesivir) to treat COVID-19 patients.
EMA is reviewing Olumiant (baricitinib) for treating COVID-19 in hospitalized patients. This includes those from 10 years old who need oxygen.
How does Olumiant (baricitinib) work?
Olumiant’s active substance, baricitinib, blocks enzymes called Janus kinases. These enzymes play a big role in inflammation and joint damage in rheumatoid arthritis.
By stopping these enzymes, baricitinib reduces inflammation and symptoms of the disease.
Where has Olumiant (baricitinib) been approved?
Olumiant (baricitinib) is approved for treating moderate to severe rheumatoid arthritis. It’s for patients who haven’t responded well to other treatments or can’t tolerate them. It was approved by:
- European Medical Agency (EMA), European Union, February 2, 2017
- Therapeutic Goods Administration (TGA), Australia, January 23, 2018
- Food and Drug Administration (FDA), USA, May 31, 2018.
The FDA also granted emergency use authorization on November 19, 2020. Now, Olumiant alone is authorized for COVID-19 treatment.
EMA started evaluating Olumiant for treating COVID-19 in hospitalized patients. This includes those from 10 years old who need oxygen.
This medicine may be approved in other regions too. If you have questions about its approval in a specific country, contact our support team.
How is Olumiant (baricitinib) taken?
The usual dose is
- 2 to 4mg once a day.
The dose may be lowered to 2mg once a day. This is when the disease is controlled or under certain conditions like kidney function or age.
Warning: Serious infections leading to hospitalization or death, including tuberculosis and bacterial, invasive fungal, viral, and other opportunistic infections, have occurred in patients receiving Olumiant (baricitinib).
For more details on dosage and administration, see the official prescribing information in our references section.
Note: Please consult with your treating doctor for personalized dosing.
Are there any known side effects or adverse reactions of Olumiant (baricitinib)?
Common adverse reactions
The most common side effects include:
- upper respiratory tract infections
- nausea
- herpes simplex
- herpes zoster
- changes in lymphocytes, neutrophils, hemoglobin, liver enzymes, and lipids.
Serious adverse reactions
The serious side effects listed include
- serious infections that can lead to hospitalization or death, such as tuberculosis and other opportunistic infections
- thrombosis, including deep venous thrombosis, pulmonary embolism, and arterial thrombosis
Use in specific populations
Olumiant (baricitinib) is not recommended for those with severe liver or kidney problems. There’s not enough data for its use in pregnant women. It’s best to avoid breastfeeding.